Elizabeth A. Garofalo - 08 Mar 2024 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Director
Signature
/s/ Nathaniel Adams, Attorney-in-fact
Issuer symbol
XENE
Transactions as of
08 Mar 2024
Net transactions value
-$95,617
Form type
4
Filing time
11 Mar 2024, 20:09:29 UTC
Previous filing
06 Dec 2023
Next filing
31 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XENE Common Shares Options Exercise $64,960 +3,500 $18.56* 3,500 08 Mar 2024 Direct
transaction XENE Common Shares Tax liability $64,993 -1,408 -40% $46.16 2,092 08 Mar 2024 Direct F1
transaction XENE Common Shares Sale $95,583 -2,092 -100% $45.69 0 08 Mar 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -3,500 -18% $0.000000 16,500 08 Mar 2024 Common Shares 20,000 $18.56 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the closing price of the Company's common shares on March 7, 2024 for purposes of net settlement calculations.
F2 One-third of the total shares subject to the Option vested on the one year anniversary of the grant date, one-third of the total shares subject to the Option vested on the two year anniversary of the grant date, and one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date.